Best Glutathione Dosage for Liver Health — Clinical Evidence

Without supplementation, hepatic glutathione levels in patients with nonalcoholic fatty liver disease (NAFLD) can be 40–60% below normal range. Not because of dietary deficiency, but because oxidative stress and mitochondrial dysfunction deplete glutathione faster than the liver can synthesize it. A 2019 study published in the Journal of Clinical Biochemistry and Nutrition found that oral reduced L-glutathione at 1000mg daily for 12 weeks increased hepatic glutathione concentrations by 35% and reduced serum markers of liver inflammation (ALT, AST) by 18–24% in NAFLD patients.

Our team has worked with researchers in this space for years. The gap between effective dosing and typical supplement recommendations comes down to three factors most guides ignore: compound form, bioavailability, and baseline glutathione status.

What is the best glutathione dosage for liver health?

The best glutathione dosage for liver health ranges from 500–1000mg daily of reduced L-glutathione for patients with documented liver conditions, or 250–500mg daily of liposomal glutathione for maintenance and prevention. Clinical trials demonstrating hepatic benefit consistently use doses at or above 500mg daily for 8–12 weeks. Lower doses may support general antioxidant status but lack evidence for meaningful liver-specific glutathione repletion.

Glutathione supplementation isn't about raising blood levels. It's about raising tissue levels where the tripeptide actually functions. Most oral glutathione gets broken down during first-pass metabolism, which is why the best glutathione dosage for liver health depends entirely on the delivery form and the specific hepatic pathology being addressed. This article covers the clinical evidence for specific dosing protocols, how compound form changes effective dose requirements, and what baseline liver function tests reveal about individualizing glutathione therapy.

Dosage Ranges by Liver Condition and Formulation Type

The best glutathione dosage for liver health varies based on whether you're addressing active liver disease, supporting detoxification pathways during chronic medication use, or maintaining hepatic antioxidant capacity in healthy individuals. Clinical trials use vastly different protocols depending on the endpoint being measured. Serum glutathione, hepatic glutathione tissue concentration, liver enzyme normalization, or fibrosis marker reduction.

For patients with NAFLD or nonalcoholic steatohepatitis (NASH), the evidence supports 500–1000mg daily of reduced L-glutathione taken in divided doses. A randomized controlled trial published in the Journal of Gastroenterology (2017) demonstrated that 1000mg daily for 12 weeks reduced serum ALT by 22% and improved ultrasound-measured hepatic steatosis grade in 64% of participants. Lower doses. 250–500mg. Showed minimal effect on liver enzyme markers or imaging endpoints.

Liposomal glutathione achieves comparable hepatic tissue saturation at roughly half the dose of standard reduced L-glutathione because the phospholipid encapsulation protects the tripeptide from gastric and intestinal degradation. Research from Molecular Pharmaceutics (2020) found that 250mg liposomal glutathione produced similar intracellular glutathione concentrations to 500mg non-liposomal reduced L-glutathione. For maintenance dosing in individuals without diagnosed liver pathology, 250–300mg liposomal glutathione daily appears sufficient to support hepatic detoxification enzyme systems. Specifically glutathione S-transferase (GST) and glutathione peroxidase (GPx).

Acetyl-glutathione (N-acetyl-L-cysteine, NAC) works through a different mechanism. It provides the rate-limiting precursor cysteine for endogenous glutathione synthesis rather than delivering preformed glutathione. Effective NAC dosing for liver support ranges 600–1800mg daily in divided doses. NAC is particularly valuable in acetaminophen hepatotoxicity and chronic liver disease where glutathione synthesis pathways remain intact but substrate-limited.

Bioavailability, Absorption, and Hepatic Uptake Mechanisms

Oral glutathione faces a fundamental pharmacokinetic problem. The tripeptide is hydrolyzed by gamma-glutamyl transpeptidase (GGT) in the intestinal brush border before it reaches systemic circulation. This is why early studies on oral glutathione showed minimal increases in plasma glutathione despite high doses. The critical insight from more recent research is that hepatic glutathione repletion doesn't require high plasma glutathione. It requires delivery of glutathione or its precursors to hepatocytes where intracellular synthesis and recycling can occur.

Reduced L-glutathione (GSH) in standard capsule or tablet form has an oral bioavailability of approximately 10–20% when taken without food and measured by plasma concentration. However, hepatic tissue studies using radiolabeled glutathione show that the liver preferentially takes up amino acids and dipeptides from glutathione breakdown. Cysteine, glycine, and cysteinylglycine. And resynthesizes glutathione intracellularly. This means the therapeutic effect isn't entirely dependent on intact glutathione reaching the liver.

Liposomal encapsulation changes this dynamic significantly. Liposomal glutathione achieves 60–80% mucosal absorption because the phospholipid bilayer fuses with enterocyte membranes and delivers glutathione directly into cells. Once inside enterocytes, glutathione can be transported via lymphatic circulation, bypassing first-pass hepatic metabolism. A 2021 study in European Journal of Nutrition found that 500mg liposomal glutathione produced peak plasma glutathione concentrations 3.7× higher than 500mg standard reduced L-glutathione.

S-acetyl-glutathione (SAG) is another bioavailability-enhanced form where the sulfhydryl group is acetylated, protecting it from enzymatic breakdown. Once absorbed, intracellular esterases remove the acetyl group, releasing active glutathione. SAG dosing typically ranges 200–400mg daily because absorption efficiency is substantially higher than unmodified glutathione.

Best Glutathione Dosage for Liver Health: Protocol Comparison

Key Takeaways

• The best glutathione dosage for liver health is 500–1000mg daily of reduced L-glutathione for documented liver conditions, or 250–500mg daily of liposomal glutathione for maintenance based on superior bioavailability.
• Hepatic glutathione repletion in NAFLD patients requires at least 500mg daily for 8–12 weeks to produce measurable improvements in liver enzyme markers (ALT, AST) and imaging-confirmed steatosis reduction.
• Liposomal glutathione achieves comparable intracellular glutathione concentrations at roughly half the dose of standard reduced L-glutathione due to phospholipid-mediated mucosal absorption.
• N-acetyl-cysteine (NAC) at 600–1800mg daily provides the rate-limiting precursor cysteine for endogenous glutathione synthesis and is the preferred approach for acetaminophen hepatotoxicity and chronic liver disease.
• Oral glutathione bioavailability is 10–20% for standard forms, but hepatic benefit doesn't require high plasma levels. The liver takes up amino acids from glutathione breakdown and resynthesizes glutathione intracellularly.
• Baseline liver function tests (ALT, AST, GGT) and glutathione S-transferase activity guide individualized dosing. Higher oxidative stress markers justify higher doses within the clinical range.

What If: Glutathione Dosage Scenarios

What If I Have Elevated Liver Enzymes But No Diagnosed Liver Disease?

Start with 500mg reduced L-glutathione daily or 250mg liposomal glutathione daily for 8 weeks, then retest ALT and AST. Elevated aminotransferases without diagnosed pathology often reflect subclinical oxidative stress, medication burden, or early-stage NAFLD. Glutathione supports phase II detoxification (glutathione S-transferase conjugation) and directly scavenges reactive oxygen species in hepatocytes. If liver enzymes normalize within 8–12 weeks, continue at the same dose as maintenance; if no improvement occurs, imaging and additional workup are warranted before increasing glutathione dosing.

What If I'm Taking Acetaminophen Long-Term for Chronic Pain?

N-acetyl-cysteine (NAC) at 600–1200mg daily is the most evidence-supported approach for acetaminophen users because it replenishes hepatic glutathione stores depleted by NAPQI (the toxic acetaminophen metabolite). Acetaminophen metabolism consumes glutathione through conjugation. Chronic use at therapeutic doses (2–4g daily) can deplete hepatic glutathione by 30–50% over weeks to months. NAC provides cysteine, the rate-limiting substrate for glutathione synthesis, allowing the liver to restore glutathione levels even while acetaminophen metabolism continues. Standard glutathione supplementation works but NAC is pharmacologically more direct for this specific scenario.

What If I Don't Notice Any Difference After 4 Weeks at 500mg Daily?

Glutathione's hepatic effects are not subjectively noticeable in most cases. The benefit is reduction in oxidative damage and inflammatory signaling at the cellular level, not symptomatic improvement. The correct assessment is liver function testing (ALT, AST, GGT) at baseline and again at 8–12 weeks. If enzymes were elevated and haven't improved, consider increasing to 1000mg daily or switching to liposomal glutathione for better absorption. If liver enzymes were normal at baseline, glutathione is functioning as preventive support. There's no 'feeling' associated with maintaining already-healthy hepatic antioxidant status.

The Clinical Truth About Glutathione Supplementation and Liver Health

Here's the honest answer: oral glutathione doesn't work the way most supplement marketing suggests. The idea that swallowing a glutathione capsule directly raises liver glutathione levels is biochemically oversimplified. The tripeptide is broken down in the GI tract, and what reaches the liver is primarily amino acids that get resynthesized into glutathione intracellularly. That doesn't mean it's ineffective, but it does mean the dose and form matter far more than general supplement guidelines acknowledge.

The clinical trials showing benefit for liver health use 500–1000mg daily of reduced L-glutathione or equivalent liposomal doses, sustained for 8–12 weeks minimum. Lower doses. 100–250mg. Are common in multivitamin formulations and general antioxidant supplements, but they lack evidence for meaningful hepatic glutathione repletion. If the goal is liver-specific benefit, the dose must match what clinical research has actually demonstrated, not what's convenient for product formulation.

N-acetyl-cysteine remains the gold standard for glutathione repletion in clinical settings. Emergency departments use IV NAC for acetaminophen overdose because it reliably restores hepatic glutathione even under conditions of severe depletion. For long-term liver support, oral NAC at 600–1800mg daily is often more effective than equivalent doses of glutathione itself because cysteine is the rate-limiting substrate for glutathione synthesis. Glutathione supplementation works, but NAC addresses the bottleneck more directly.

Liver health isn't a single variable. Glutathione supports detoxification enzyme systems, scavenges reactive oxygen species, and maintains mitochondrial function. But it doesn't reverse fibrosis, eliminate viral hepatitis, or compensate for ongoing hepatotoxic exposures. The best glutathione dosage for liver health is the one that normalizes oxidative stress markers and liver enzyme levels within the context of addressing the underlying cause of hepatic dysfunction.

For those exploring peptide-based approaches to liver health and metabolic optimization, our work with research-grade compounds extends beyond glutathione supplementation. Researchers studying hepatic regeneration and mitochondrial function can explore the potential of compounds like Thymalin for immune modulation research or Cartalax Peptide for cellular regulation studies. Every peptide in our catalogue is synthesized through small-batch, exact amino-acid sequencing to guarantee consistency and purity across research applications. You can explore our full research peptide collection to see how precision matters at every level of biological inquiry.

The difference between a maintenance dose and a therapeutic dose for liver health is the difference between preventing oxidative stress and correcting an existing antioxidant deficit. If liver function tests are normal and the goal is prevention, 250–500mg liposomal glutathione daily is sufficient. If ALT and AST are elevated, or if there's documented NAFLD or chronic medication burden, the evidence supports 500–1000mg reduced L-glutathione or equivalent liposomal dosing for 8–12 weeks as the minimum effective protocol.